+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cardiac Biomarker Market Research Report by Type, Location of Testing, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4989935
  • Report
  • April 2022
  • Region: Global
  • 212 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • bioMérieux SA
  • F. Hoffmann-La Roche Ltd.
  • Johnson and Johnson
  • Olympus Corporation
The Global Cardiac Biomarker Market size was estimated at USD 3,519.91 million in 2021, USD 4,034.69 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 14.80% to reach USD 8,057.98 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Cardiac Biomarker to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market was studied across Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, and Troponins (T and I).
  • Based on Location of Testing, the market was studied across Laboratory Testing and Point of Care Testing.
  • Based on Application, the market was studied across Acute Coronary Syndrome, Atherosclerosis, Congestive Heart Failure, and Myocardial Infarction.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cardiac Biomarker market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cardiac Biomarker Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cardiac Biomarker Market, including Abbott Laboratories, Beckman Coulter, Inc., bioMérieux SA, F. Hoffmann-La Roche Ltd., Johnson and Johnson, Olympus Corporation, PerkinElmer Inc., Roche Diagnostics Limited, Siemens Healthcare GmbH, and Tosoh Corporation.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Cardiac Biomarker Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cardiac Biomarker Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cardiac Biomarker Market?
4. What is the competitive strategic window for opportunities in the Global Cardiac Biomarker Market?
5. What are the technology trends and regulatory frameworks in the Global Cardiac Biomarker Market?
6. What is the market share of the leading vendors in the Global Cardiac Biomarker Market?
7. What modes and strategic moves are considered suitable for entering the Global Cardiac Biomarker Market?
Frequently Asked Questions about the Global Cardiac Biomarker Market

What is the estimated value of the Global Cardiac Biomarker Market?

The Global Cardiac Biomarker Market was estimated to be valued at $3519.9 Million in 2021.

What is the growth rate of the Global Cardiac Biomarker Market?

The growth rate of the Global Cardiac Biomarker Market is 14.8%, with an estimated value of $8058.0 Million by 2027.

What is the forecasted size of the Global Cardiac Biomarker Market?

The Global Cardiac Biomarker Market is estimated to be worth $8058.0 Million by 2027.

Who are the key companies in the Global Cardiac Biomarker Market?

Key companies in the Global Cardiac Biomarker Market include Abbott Laboratories, Beckman Coulter, Inc., bioMérieux SA, F. Hoffmann, La Roche Ltd., Johnson and Johnson, Olympus Corporation, PerkinElmer Inc. and Siemens Healthcare GmbH.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • bioMérieux SA
  • F. Hoffmann-La Roche Ltd.
  • Johnson and Johnson
  • Olympus Corporation

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of cardiovascular diseases globally
5.1.1.2. Increasing awareness and need for early diagnosis of cardiovascular diseases
5.1.1.3. Surge in geriatric population and related heart diseases
5.1.2. Restraints
5.1.2.1. Technical issues pertinent to sample collection and storage
5.1.3. Opportunities
5.1.3.1. Emerging investment in research and development activities in cardiac biomarkers
5.1.3.2. Emerging demand for POC testing with cardiac biomarkers
5.1.4. Challenges
5.1.4.1. Concerns over regulatory and reimbursement systems
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Cardiac Biomarker Market, by Type
6.1. Introduction
6.2. Brain Natriuretic Peptide (BNPs) or NT-proBNP
6.3. Ischemia Modified Albumin (IMA)
6.4. Myocardial Muscle Creatine Kinase (CK-MB)
6.5. Myoglobin
6.6. Troponins (T and I)
7. Cardiac Biomarker Market, by Location of Testing
7.1. Introduction
7.2. Laboratory Testing
7.3. Point of Care Testing
8. Cardiac Biomarker Market, by Application
8.1. Introduction
8.2. Acute Coronary Syndrome
8.3. Atherosclerosis
8.4. Congestive Heart Failure
8.5. Myocardial Infarction
9. Americas Cardiac Biomarker Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cardiac Biomarker Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Cardiac Biomarker Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories
13.2. Beckman Coulter, Inc.
13.3. bioMérieux SA
13.4. F. Hoffmann-La Roche Ltd.
13.5. Johnson and Johnson
13.6. Olympus Corporation
13.7. PerkinElmer Inc.
13.8. Roche Diagnostics Limited
13.9. Siemens Healthcare GmbH
13.10. Tosoh Corporation
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL CARDIAC BIOMARKER MARKET: DYNAMICS
FIGURE 2. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2027
FIGURE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP, 2019-2027 (USD MILLION)
FIGURE 6. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ISCHEMIA MODIFIED ALBUMIN (IMA), 2019-2027 (USD MILLION)
FIGURE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ISCHEMIA MODIFIED ALBUMIN (IMA), BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB), 2019-2027 (USD MILLION)
FIGURE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB), BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS (T AND I), 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS (T AND I), BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2021 VS 2027 (%)
FIGURE 16. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2021 VS 2027 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2027
FIGURE 18. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, 2019-2027 (USD MILLION)
FIGURE 19. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 20. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 23. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2027
FIGURE 25. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2019-2027 (USD MILLION)
FIGURE 26. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 27. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ATHEROSCLEROSIS, 2019-2027 (USD MILLION)
FIGURE 28. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 29. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2019-2027 (USD MILLION)
FIGURE 30. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 31. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, 2019-2027 (USD MILLION)
FIGURE 32. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 33. AMERICAS CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 34. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 35. BRAZIL CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 36. CANADA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. MEXICO CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. CHINA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. INDIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. INDONESIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. JAPAN CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. TAIWAN CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. THAILAND CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. FRANCE CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. GERMANY CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. ITALY CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 55. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. QATAR CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. RUSSIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 60. SPAIN CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 62. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 63. GLOBAL CARDIAC BIOMARKER MARKET: FPNV POSITIONING MATRIX
FIGURE 64. GLOBAL CARDIAC BIOMARKER MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 65. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CARDIAC BIOMARKER MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL CARDIAC BIOMARKER MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ISCHEMIA MODIFIED ALBUMIN (IMA), BY REGION, 2019-2027 (USD MILLION)
TABLE 10. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY ISCHEMIA MODIFIED ALBUMIN (IMA), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY ISCHEMIA MODIFIED ALBUMIN (IMA), BY STATE, 2019-2027 (USD MILLION)
TABLE 12. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY ISCHEMIA MODIFIED ALBUMIN (IMA), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY ISCHEMIA MODIFIED ALBUMIN (IMA), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 14. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB), BY REGION, 2019-2027 (USD MILLION)
TABLE 15. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB), BY STATE, 2019-2027 (USD MILLION)
TABLE 17. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2019-2027 (USD MILLION)
TABLE 20. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY STATE, 2019-2027 (USD MILLION)
TABLE 22. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS (T AND I), BY REGION, 2019-2027 (USD MILLION)
TABLE 25. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS (T AND I), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS (T AND I), BY STATE, 2019-2027 (USD MILLION)
TABLE 27. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS (T AND I), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS (T AND I), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2019-2027 (USD MILLION)
TABLE 30. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2019-2027 (USD MILLION)
TABLE 31. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY STATE, 2019-2027 (USD MILLION)
TABLE 33. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2019-2027 (USD MILLION)
TABLE 36. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY STATE, 2019-2027 (USD MILLION)
TABLE 38. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 40. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 41. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2019-2027 (USD MILLION)
TABLE 42. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 43. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY STATE, 2019-2027 (USD MILLION)
TABLE 44. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 46. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 47. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 48. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY ATHEROSCLEROSIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 49. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 51. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2019-2027 (USD MILLION)
TABLE 52. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 53. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY STATE, 2019-2027 (USD MILLION)
TABLE 54. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 56. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2019-2027 (USD MILLION)
TABLE 57. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 58. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY STATE, 2019-2027 (USD MILLION)
TABLE 59. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 61. AMERICAS CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 62. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 63. BRAZIL CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 64. CANADA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 65. MEXICO CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 66. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 67. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 68. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 69. CHINA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 70. INDIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 71. INDONESIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 72. JAPAN CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 73. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 74. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 75. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 76. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 77. TAIWAN CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 78. THAILAND CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 80. FRANCE CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 81. GERMANY CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 82. ITALY CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 83. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 84. QATAR CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 85. RUSSIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 86. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 87. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 88. SPAIN CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 89. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 90. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 91. GLOBAL CARDIAC BIOMARKER MARKET: SCORES
TABLE 92. GLOBAL CARDIAC BIOMARKER MARKET: BUSINESS STRATEGY
TABLE 93. GLOBAL CARDIAC BIOMARKER MARKET: PRODUCT SATISFACTION
TABLE 94. GLOBAL CARDIAC BIOMARKER MARKET: RANKING
TABLE 95. GLOBAL CARDIAC BIOMARKER MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 96. GLOBAL CARDIAC BIOMARKER MARKET: MERGER & ACQUISITION
TABLE 97. GLOBAL CARDIAC BIOMARKER MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 98. GLOBAL CARDIAC BIOMARKER MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 99. GLOBAL CARDIAC BIOMARKER MARKET: INVESTMENT & FUNDING
TABLE 100. GLOBAL CARDIAC BIOMARKER MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 101. GLOBAL CARDIAC BIOMARKER MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • bioMérieux SA
  • F. Hoffmann-La Roche Ltd.
  • Johnson and Johnson
  • Olympus Corporation
  • PerkinElmer Inc.
  • Roche Diagnostics Limited
  • Siemens Healthcare GmbH
  • Tosoh Corporation
Note: Product cover images may vary from those shown

Loading
LOADING...